Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced unaudited fourth quarter and full-year 2013 revenues and a pipeline update as the Company positions itself to achieve its Building Blocks of Growth long-range goals. Cubist delivered 22% total net revenue growth in the fourth quarter compared to 2012, and CUBICIN® (daptomycin for injection) achieved blockbuster status with over $1 billion in worldwide sales for the full year.
Help employers find you! Check out all the jobs and post your resume.
